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Abstract
Background: Complementary and alternative medicine (CAM) is widespread but has various utilization rates
according to country and the condition of patients. Generally, CAM is more frequently used in diseases that have
no clear treatment method in conventional medicine. Therefore, a high utilization rate of CAM can be assumed in
pediatric neurological diseases, but few studies have investigated the utilization of CAM in children with
neuropsychiatric diseases. In particular, studies regarding the current use of CAM are scarce.
Methods: We conducted a survey of the parents or caregivers of patients who visited the pediatric rehabilitation
clinic, pediatric neurology clinic, or pediatric psychiatry clinic at one university hospital from April to July 2011. We
analyzed the factors that affect the utilization of CAM and other rehabilitation therapies.
Results: Among the 578 patients recruited, 258 patients have ever received CAM (51.5 %), and the current CAM
utilization rate was 19.0 % (110 patients). Two hundred patients (34.6 %) were currently receiving only other
rehabilitation therapies, and 268 patients (46.4 %) were currently receiving no type of therapy. The rate of current
CAM usage was significantly high in epilepsy patients.
The ORs of 1–6-year-old and 7–12-year-old children compared with 13–19-year-old children were 3.14 (95 % CI
1.31–7.53) and 3.34 (95 % CI 1.64–6.79), respectively, and the OR of the group with longer disease duration
(≥48 months) compared with the group with shorter disease duration was 3.36 (95 % CI 1.71–6.59). Only the age
and disease duration showed statistically significant differences between the patients who were administered CAM
and those who received other rehabilitation therapies (p < 0.0001).
Conclusions: CAM is preferred by patients under 13 years of age compared with patients aged 13–19 years,
whereas other rehabilitation therapies are preferred by patients aged 1–6 years, followed by those aged 6–12 years
and then by those aged 13–19 years. The patient’s age and disease duration are the major factors influencing CAM
use. Future studies should specify particular diseases, rather than combining all types of neuropsychiatric diseases,
and include the socio-economic status of the parents.
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Background
Complementary and alternative medicine (CAM) is de-
fined as “a broad domain of healing resources that en-
compasses all health systems, modalities, and practices,
and their accompanying theories and beliefs, other than
those intrinsic to the politically dominant health systems
of a particular society or culture in a given historical
period” [1]. CAM is used worldwide [2–6], and many
national surveys have proven that CAM is widespread
[7]. In certain African or Asian countries, CAM is used
as the primary method of health care in the form of
traditional medicine [8].
Some population-based studies have shown that 1/3 to
2/3 of the subjects were using CAM [4, 5]; however,
population-based studies on children are scarce. Accord-
ing to a study conducted in the USA based on the 1996
Medical Expenditure Panel Survey database, pediatric
CAM use is reported to be as low as 1.8–2.0 % [9, 10].
However, previous studies conducted in other countries
found that the utilization rate ranged from a minimum
of 13 % to a maximum of 80 % [4]. These were either
hospital-based studies or studies that focused on children
with specific diseases. A higher use of CAM was found in
severe intractable diseases, such as tumors, or neuro-
logical diseases such as cerebral palsy (CP) [11–15]. A
Korean study demonstrated that 35 % of school-aged
children in the general population have used CAM
[16], and in another study, 63.5 % of the children
with a chronic disease were using CAM [17].
A high utilization rate of CAM can be assumed with
pediatric neurological diseases because these conditions
are usually chronic and intractable, but few studies have
investigated this assumption. A study on the use of
CAM in children with CP in the USA reported that
56 % of the subjects had ever received CAM [18]. A
study that was performed in Canada in 2005 reported
that 44 % of the children with neurological disorders
had received CAM [11], and a study in Israel reported
that 7.5 % of the children with attention deficit hyper-
activity disorder (ADHD) and 14 % of the children with
epilepsy were currently using CAM and that 51.5 % of
the children with epilepsy had ever undergone treatment
with CAM [19]. A Korean study on pediatric epilepsy re-
ported that 17.2 % of the subjects had ever taken trad-
itional Korean herbal medicine as a CAM approach [20].
In Korea, previous studies have focused on the use of
traditional Korean herbal medicine and acupuncture,
and research on the general use of CAM is lacking.
Additionally, a past experience with CAM was sur-
veyed [21, 22], but a study on the current use is still
required. This study was conducted to investigate the
current use of CAM in Korea in children with neuro-
logical or psychiatric diseases and the factors that
affect the use of CAM.
Methods
Methods
A survey was conducted of the parents or caregivers of
patients who visited the pediatric rehabilitation clinic
(Additional file 1), pediatric neurology clinic or pediatric
psychiatric clinic at one university hospital between
April and July, 2011. After this study was approved by
the Institutional Review Board, we explained the study
to all the parents and caregivers, and those who signed
the informed consent form were included. Patients
under 1 or over 20 years of age were excluded. The
guardians completed a questionnaire after listening to a
detailed description by an interviewer. The self-reported
questionnaire consisted of 12 multiple-choice questions,
and the guardians were instructed to report the patient’s
primary diagnosis, date of diagnosis, health problems
other than the diagnosed disease, use of CAM in the past
or present, and use of other rehabilitation therapies not
included in CAM. “CAM use” was defined as the use of
dietary supplements that do not need a doctor’s prescrip-
tion, acupuncture therapy, traditional herbal medicine,
neurofeedback, massage and other such therapies according
to the definition and general situation reported by the
WHO [23] and the National Center for Complementary
and Alternative Medicine (NCCAM) [24]. “Other rehabili-
tation therapies” that were not included in CAM were
defined as therapies that are prescribed or recommended
by a doctor, such as physical therapy, occupational therapy,
speech therapy, educational therapy (art, music, play),
psychological counseling and cognitive behavioral therapy.
Statistical analysis
The general and clinical characteristics of the subjects
were summarized using frequencies and percentages for
categorical data and means ± standard deviation and
median (range) for continuous data.
For categorical data, the Chi-square test was used to
analyze the correlation between the subject characteristics
and CAM use, and for continuous data, a t-test or analysis
of variance (ANOVA) was used. The Tukey-Kramer test
was used for a post hoc analysis after the ANOVA.
To determine the variables that affect the use of CAM,
univariate and multivariate multinomial logistic regression
analyses were used. Additionally, the adjusted odds ratio
(OR) and 95 % confidence interval (CI) were calculated
using a multivariate logistic regression analysis, which
considers several covariates simultaneously. The statistical
significance was set below 0.05, and the SPSS 18.0 soft-
ware was used for the analysis.
Results
A total of 596 copies of questionnaires were collected,
and 18 were excluded from the analysis because of am-
biguous answers; 578 questionnaires were thus finally
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analyzed. The number of patients who had ever received
CAM was 258 (51.5 %). As presented in Table 1, 110 pa-
tients were currently using CAM with or without other
rehabilitation therapies (19.0 %). Regarding the type of
CAM, 72 patients (12.5 %) reported the use of dietary
supplements, and 24 (4.1 %) used traditional Korean
herbal medicine, while 13 (2.2 %) used acupuncture.
There were 200 subjects who were currently receiving
other rehabilitation therapies only (34.6 %), and 268
were currently receiving neither of the treatments
(46.4 %). Among the patients, 328 out of 578 were boys
(56.7 %), and 250 were girls (43.3 %); there was a signifi-
cant difference in the sex ratios among the three groups
(P < 0.05). The mean age of the patients was 8.9 ±
4.9 years, and 227 patients (39.3 %) were in elementary
school, which was the highest rate (39.3 %). The mean
age of the group currently using CAM was 8.6 ± 4.0 years,
and 54 subjects (49.1 %) were elementary school students
(7–12 years old). There was a significant difference in the
mean ages among the three groups (P < 0.0001).
Table 2 contains the patients’ clinical characteristics.
Epilepsy was the most frequent diagnosis (67.3 %) and
the primary diagnosis that was associated with the use of
CAM or other rehabilitation therapies (P < 0.0001). The
rate of current CAM usage was significantly high in epi-
lepsy patients. The rate of receiving other rehabilitation
therapies without CAM was significantly high in CP
patients.
Three groups, which were formed based on the use of
CAM and other rehabilitation therapies, exhibited a dif-
ference in the mean value of disease duration (P =
0.015); the group that received neither CAM nor other
rehabilitation therapies had the shortest disease duration
(55.5 ± 49.4 months). When the patients were divided
into two groups according to the median duration of dis-
ease (48 months), the current use of CAM and disease
duration were significantly related (P < 0.0001). In the
group receiving CAM or other rehabilitation therapies,
the ratio of disease duration over 48 months was 74.4 and
75.8 % each, whereas the group that was receiving neither
treatment approach had a ratio of 53.8 %.
Health problems other than the primarily diagnosed
disease were related to the use of CAM (P = 0.016). The
group that was receiving neither CAM nor other re-
habilitation therapies had a significantly smaller number
of health problems than the other groups (P = 0.007).
Among the health problems, growth retardation and
frequent colds were associated with the use of CAM
(P < 0.0001 and P = 0.017, respectively).
A multinomial logistic regression analysis was con-
ducted to identify the crude OR for CAM use (Table 3).
In boys, the OR of CAM use was found to be 0.84 [95 %
confidence interval (CI): 0.54–1.30]. In the boys who
were not using CAM, the OR of receiving other rehabili-
tation therapies was 1.45 times (95 % CI: 1.00–2.12)
higher than that of the girls. In the patients who were
1–6 years of age, the odds of using CAM was 2.48 times
(95 % CI: 1.32–4.65 times) higher than that of those
aged 13–19 years. In addition, among the patients who
were not using CAM, those who were 1–6 years of age
had a odds of receiving other rehabilitation therapies
that was 4.64 times (95 % CI: 2.78–7.74 times) higher
than that of those aged 13–19 years. For patients with a
disease duration equal to or more than 48 months, the
odds of using CAM was 2.50 times (95 % CI: 1.28–4.50)
higher than that of those with a disease duration of less
than 48 months (P < 0.001). The OR of using CAM in those
who had health problems was 1.38 (95 % CI: 0.88–2.17).
Table 1 Patient characteristics
Variable Overall CAM P value






All participants 578 (100.0) 110 (19.0) 200 (34.6) 268 (46.4)
Sex
Male 328 (56.7) 55 (50.0) 127 (63.5) 146 (54.5) 0.042
Female 250 (43.3) 55 (50.0) 73 (36.5) 122 (45.5)
Age (years)
Mean ± SD 8.9 ± 4.9 8.6 ± 4.0aa 7.3 ± 4.5b 9.9 ± 5.2c <0.0001
Median (range) 9 (1–19) 9 (1–19) 6 (1–19) 10 (1–19)
Age (years)
1–6 years (preschooler) 206 (35.6) 36 (32.7) 101 (50.5) 69 (25.7) <0.0001
7–12 years (primary school child) 227 (39.3) 54 (49.1) 69 (34.5) 104 (38.8)
13–19 years (middle and high school child) 145 (25.1) 20 (18.2) 30 (15.0) 95 (35.4)
aDifferences in numeric characteristics between groups were tested with an analysis of variance (ANOVA) with the Tukey-Kramer post-hoc test. Means with different
scripts are different from each other (P < 0.05)
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Furthermore, a multivariate multinomial logistic re-
gression analysis was performed to identify the adjusted
OR for CAM use (Table 4). Compared with the children
who were 13–19 years old, those who were 1–6 years
old and those who were 7–12 years old had more fre-
quent use of CAM by 3.14-fold (95 % CI:1.31–7.53) and
3.34-fold (95 % CI:1.64–6.79), respectively. The patients
who had a disease duration equal to or more than
48 months had a 3.36 times (95 % CI: 1.71–6.59) higher
utilization rate of CAM than that of those who had less
than a 48-month disease duration. In the other rehabili-
tation therapies group, those aged 1–6 years and 7–12
years were 6.92 times (95 % CI: 3.40–14.1) and 2.31
times (95 % CI: 1.36–4.22) more likely to use CAM than
those aged 13–19 years, respectively. Moreover, patients
who had a disease duration equal to or more than
48 months exhibited a 5.58 times (95 % CI: 3.06–10.2)
higher utilization rate of other rehabilitation therapies.
Discussion
This study separately investigated both the experience
with each treatment and the current use of the treat-
ment; information regarding the experience rate and the
current utilization rate were thus differentially obtained.
First, focusing on ever having had CAM, the present
study revealed that the experience rate for CAM was
51.5 %, which was higher than the rate of experiencing
CAM in children who visited a neurologic clinic in
Canada (44 %) [11] and lower than that of children with
a brain injury in the United Kingdom (UK, 59 %) [25].
Although we were unable to compare these populations
directly because the CAM list in each study consisted of
Table 2 Clinical condition of patients
Variable Overall CAM P value







Epilepsy 389 (67.3) 85 (77.3) 101 (50.5) 203 (75.7) <0.0001
CP 56 (9.7) 9 (8.2) 41 (20.5) 6 (2.3)
Developmental disordera 51 (8.8) 6 (5.5) 27 (13.5) 18 (6.7)
ADHD 43 (7.4) 7 (6.4) 11 (5.5) 25 (9.3)
Others 39 (6.7) 3 (2.7) 20 (10.0) 16 (6.0)
Disease Duration (mos)
Mean ± SD 62.1 ± 47.6 65.5 ± 43.9ab 68.3 ± 46.5a 55.5 ± 49.4b 0.015
Median (range) 48 (0–229) 57 (1–211) 55 (0–229) 38 (0–226)
Disease Duration
< 48 months 137 (33.9) 20 (25.6) 37 (24.2) 80 (46.2) <0.0001
≥ 48 months 267 (66.1) 58 (74.4) 116 (75.8) 93 (53.8)
Having Health Problems
Yes 341 (59.0) 67 (60.9) 132 (66.0) 142 (53.0) 0.016
No 237 (41.0) 43 (39.1) 68 (34.0) 126 (47.0)
Number of Health Problems
Mean ± SD 0.8 ± 0.9 0.9 ± 0.9ab 0.9 ± 0.9a 0.7 ± 0.8b 0.007
Median (range) 1 (0–5) 1 (0–4) 1 (0–5) 1 (0–4)
Health Problems
Atopic dermatitis 60 (10.4) 10 (9.1) 20 (10.0) 30 (11.2) 0.81
Allergic rhinitis 103 (17.8) 21 (19.1) 27 (13.5) 55 (20.5) 0.14
Asthma 19 (3.3) 1 (0.9) 9 (4.5) 9 (3.4) 0.34
Dyspepsia 40 (0.9) 8 (7.3) 16 (8.0) 16 (6.0) 0.68
Growth retardation 86 (14.9) 22 (20.0) 45 (22.5) 19 (7.7) <0.0001
Enuresis 13 (2.2) 2 (1.8) 7 (3.5) 4 (1.5) 0.33
Frequent URI 125 (21.6) 30 (27.3) 51 (25.5) 44 (16.4) 0.017
Others 23 (4.0) 3 (2.7) 12 (6.0) 8 (3.0) 0.19
aDevelopmental disorder other than CP
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different therapies and the disease in each study also
differed, approximately one-half of the children with
neuropsychiatric diseases generally seemed to have
experienced CAM. Focusing on a specific disease, the
above-mentioned Canadian study indicated an experience
rate of 39 % in epilepsy and 38 % in brain injuries [11],
and another study conducted in Canada revealed an
experience rate of 35.3 % in CP [26]. These results
cannot be directly compared, but the studies found a
relatively lower experience rate than our present
study, which mainly included patients with epilepsy
and CP.
Next, regarding the current utilization rate, our
present study revealed a 19.0 % utilization rate at the
time the survey was performed (21.9 % in epilepsy,
16.1 % in CP and 11.8 % in those with a developmental
disorder). Studies on the current use are limited, but a
study conducted in the UK found a use rate of 9.4 % in
CP [27], which was lower than the result of our present
study.
This distinction can be identified in the utilization rate
according to each CAM therapy. Our study revealed a
current utilization rate of 12.5 % for dietary supple-
ments, 4.1 % for traditional Korean herbal medicine, and
Table 3 Crude ORs of current CAM use according to univariate multinomial logistic regression
Group*
Variable CAM user OR (95 % CI) CAM non-user with other rehabilitation therapies OR (95 % CI) P value**
Sex
Male 0.84 (0.54–1.30) 1.45 (1.00–2.12) 0.042
Female 1.00 1.00
Age
1–6 years 2.48 (1.32–4.65) 4.64 (2.78–7.74) <0.0001
7–12 years 2.47 (1.38–4.42) 2.10 (1.26–3.50)
13–19 years 1.00 1.00
Disease Duration
< 48 months 1.00 1.00 <0.0001
≥ 48 months 2.50 (1.38–4.50) 2.70 (1.68–4.34)
Having Health Problems
Yes 1.38 (0.88–2.17) 1.72 (1.18–2.52) 0.016
No 1.00 1.00
*Reference category: CAM non-user without other rehabilitation therapies
**Estimated P value of the association between the study variables and the polytomous outcome using the likelihood ratio test
Table 4 Adjusted ORs of current CAM use according to multivariate multinomial logistic regression
Group*
Variable CAM user OR (95 % CI) CAM non-user with other rehabilitation therapies OR (95 % CI) P value**
Sex
Male 0.85 (0.49–1.49) 1.56 (0.96–2.53) 0.067
Female 1.00 1.00
Age
1–6 years 3.14 (1.31–7.53) 6.92 (3.40–14.1) <0.0001
7–12 years 3.34 (1.64–6.79) 2.31 (1.26–4.22)
13–19 years 1.00 1.00
Disease Duration
<48 months 1.00 1.00 <0.0001
≥48 months 3.36 (1.71–6.59) 5.58 (3.06–10.2)
Having Health Problems
Yes 1.12 (0.63–1.99) 1.44 (0.88–2.37) 0.34
No 1.00 1.00
*Reference category: CAM non-user without other rehabilitation therapies
**Estimated P value of the association between the study variables and the polytomous outcome using the likelihood ratio test
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2.2 % for acupuncture. Comparing with studies that were
performed with similar diseases, Soo’s study [11] in chil-
dren who visited a pediatric neurologic clinic indicated
that 15 % used chiropractic manipulations, 12 % used
dietary therapy, 8 % used herbal remedies, 8 % used
homeopathy and 8 % used prayer/faith healing. Cheshire’s
study [25] of children with a brain injury revealed that
22.4 % used massage, 21.4 % used osteopath/cranial oste-
opathy, 18.4 % used aromatherapy, 15.3 % used omega-3
and omega-6 oil supplements and 14.3 % used homeop-
athy. In Korea, children with neuropsychiatric disease
were using a relatively limited set of CAM therapies,
whereas in western countries, patients seemed to be using
an even distribution of more varied CAM therapies.
We analyzed the patient characteristics in each CAM
group, the other rehabilitation therapies group and the
non-use group, and the results revealed a longer disease
duration in both the CAM group and the other rehabili-
tation therapies group. There were also more cases of
having other health problems in these groups. Among
the other health problems, the presence of common
upper respiratory infections was the most frequent
(27.3 %), and growth retardation was the second most
common problem (20.0 %) in CAM group.
Additionally, the mean ages of the three groups were
significantly different, and this difference was still statis-
tically significant according to the adjusted ORs. In both
the CAM and other rehabilitation therapies groups,
those aged 13–19 years used the fewest treatments. In
the CAM group, those aged 7–12 years used the most,
with an OR of 3.34, followed by those aged 1–6 years
with an OR of 3.14. In the other rehabilitation therapies
group, those aged 1–6 years used the most therapies,
with an OR of 6.92, followed by those aged 7–12 years
with an OR of 2.31. This result suggests that parents
tend to seek rehabilitation therapies as much as possible
at an early stage, and over time, some of the guardians
move to CAM treatments or others stop both types of
treatment. Hurvitz’s study [18] on CP children indicated
that the younger the patient, the higher the utilization
rate of CAM, which does not correspond with our re-
sults. This discordance might be caused by the variation
in the target diseases and types of CAM investigated and
by the difference in health care use between the two
countries. In the social context of Korea, there is in-
creasing difficulty to continue outpatient treatment as
the school year of the patients increases; therefore, we
classified the patients into three groups: 1–6 years (be-
fore entering elementary school), 7–12 years (during
elementary school), and 13–19 years (during middle
school and high school). Consequently, preschool children
were the most prevalent group in the other rehabilitation
therapies group, and elementary school children were the
most prevalent group in the CAM group. Various CAM
therapies are not widely used in Korea as mentioned earl-
ier; thus, parents seem to first encounter other rehabilita-
tion therapies which are more easily accessible, and they
seem to use CAM later when starting to seek other add-
itional treatment if the patients’ disease is not resolved
and the disease duration increases. This phenomenon cor-
responds with the results of Sanders’ study [28], which
demonstrated that CAM is more frequently used by those
with un-treatable diseases than those with treatable dis-
eases. The OR decreased from 6.92 in the 1–6-years-old
age group to 2.31 in the 7–12-years-old age group in the
other rehabilitation therapies group, but the OR increased
from 3.14 at 1–6 years of age to 3.31 at 7–12 years of age,
which implies that preschool children visit hospitals and
receive rehabilitation therapies frequently, but school-
aged children tend to change to food or drug intake,
which does not require a healthcare visit.
In the present study, we only investigated disease dur-
ation and not disease severity. When the disease duration
was divided into two groups of equal to or more than
48 months and lesser than 48 months, patients with
longer disease duration exhibited a significantly higher
utilization rate in not only the other rehabilitation therap-
ies but also the CAM group. This result corresponds with
other previous studies, and it can be interpreted that
CAM is more frequently used in chronic or severe dis-
eases. Samdup’s study [26] also showed increased CAM
use in those with greater disease severity of CP. Previous
studies also revealed that CAM use is greater in those
with more seizures in epilepsy patients [27], more severe
diseases or degree [29] of disability [22], and greater
inability of independent ambulation [18].
A limitation of this study was the lack of considering
the socio-economic factors that are known to affect
CAM use, including parents’ age, education background,
and economic level. Previous studies have shown that
parents’ past CAM use experiences affect their children’s
current CAM use [18, 25, 28, 30]; thus, it can be inferred
that decision makers’ experiences have significant effects
on their children’s treatment. In addition to the parents’
past CAM use, their socio-economic factors affect the
children’s CAM use, as shown in previous studies. A
higher parental education level [18, 22, 25], older father’s
age [18], and higher parental socio-economic status [27]
were associated with higher CAM use in children.
Greater parental agreement with CAM philosophy [25]
was also associated with more frequent CAM use com-
pared to those who do not agree.
Another limitation is that the subjects who had several
heterogeneous diseases and the severity of disease, which
can affect the use of CAM, were not objectively identified.
In addition, only the opinions of the parents and not
those of their children were surveyed. However, this
study is meaningful because we analyzed children with
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neuropsychiatric disorders, which have not been investi-
gated in previous studies. We considered their clinical
characteristics and the use of other rehabilitation therap-
ies to analyze the factors of CAM use. Further studies
are required to confine the survey to one disease with a
more detailed division of each subsection that represents
the patient characteristics. Further studies should also
evaluate various family factors such as the parents’
socio-economic level.
Conclusion
This study’s aim was to investigate the present condition
and influencing factors of CAM use among children
with neuropsychiatric disease. Patients aged 1–6 years
and 6–12 years are more frequently administered CAM
than those aged 13–19 years, whereas other rehabilita-
tion therapies without CAM are preferred by patients
aged 1–6 years, followed by patients aged 6–12 years
and then by those aged 13–19 years. Patients with long
disease durations use CAM more frequently. Further-
more, the main factors influencing CAM use are disease
duration and patient age. This study will supply useful
data for developing healthcare systems or services for
children with neuropsychiatric disease.
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